ArticleCureus2026
Reversible Isolated Opsoclonus in a Patient With Gastric Cancer and Antibodies to Glutamic Acid Decarboxylase and Myelin Oligodendrocyte Glycoprotein.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Opsoclonus and myoclonus are known paraneoplastic manifestations of malignancy. The most common antibodies found are anti-neuronal antibodies (Hu, Ri, and Ma). The most common affiliated malignancies are small-cell lung cancers, breast cancers, or gynecological malignancies. Gastric cancer is uncommon. Other antibodies have been cited, but are rare. Isolated opsoclonus without significant myoclonus is also rare. While both glutamic acid decarboxylase (GAD) and myelin oligodendrocyte glycoprotein (MOG) antibodies have individually been reported to be associated with opsoclonus, reports of a combination of these two in a patient with gastric cancer with isolated reversible opsoclonus are scarce. In this case, we follow a patient who presented as such and demonstrated significant symptomatic improvement after the administration of intravenous immunoglobulin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.